Clinical Trials Logo

Filter by:
NCT ID: NCT04904549 Recruiting - Clinical trials for COVID-19 (Healthy Volunteers)

Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older

VAT00008
Start date: May 26, 2021
Phase: Phase 3
Study type: Interventional

The primary objectives of the study are: - To assess, in participants who are severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naïve, the clinical efficacy of the SARS-CoV-2 vaccines for the prevention of symptomatic COVID-19 occurring ≥ 14 days after the second injection. - To assess the safety of the SARS-CoV-2 vaccines compared to placebo throughout the study. The key secondary objectives of the study are to assess, in SARS-CoV-2 naïve participants, the efficacy of the SARS-CoV-2 vaccines against: - SARS-CoV-2 infection occurring ≥ 14 days after the second injection. - Severe disease occurring ≥ 14 days after the second injection. - Asymptomatic infection and symptomatic COVID-19 occurring ≥ 14 days after the first injection.

NCT ID: NCT04798027 Recruiting - COVID-19 Clinical Trials

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

VAW00001
Start date: March 12, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objectives of the study are: - To describe the safety profile of all participants in each age group and each study intervention group up to 12 months post-last dose. - To describe the neutralizing antibody profile at Day 1, Day 22, and Day 36 of each study intervention group. The secondary objectives of the study are: - To describe binding antibody profile from Day 1 to Day 387 of each study intervention group. - To describe the neutralizing antibody profile from Day 90 to Day 387 of each study intervention group. - To describe the occurrence of virologically-confirmed COVID-19-like illness and serologically-confirmed SARS-CoV-2 infection. - To evaluate the correlation/association between antibody responses to SARS-CoV-2 mRNA vaccine and the risk of virologically-confirmed COVID-19-like illness and/or serologically-confirmed SARS-CoV-2 infection.

NCT ID: NCT04771013 Completed - COVID-19 Clinical Trials

Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras

Start date: February 10, 2021
Phase: Phase 2
Study type: Interventional

This is a single-arm, open-label, phase II clinical study to evaluate the safety and efficacy of thymic peptides in the treatment of hospitalized COVID-19 patients in Honduras.

NCT ID: NCT04762680 Recruiting - Clinical trials for COVID-19 (Healthy Volunteers)

Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older

VAT00002
Start date: February 24, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objectives of the study are: - To assess the safety profile of the study vaccines in each study intervention group. - To assess the neutralizing antibody profile after primary series vaccination in SARS-CoV-2-naïve adults. - To demonstrate that a booster dose of monovalent or bivalent SARS-CoV-2 vaccine given to adults previously vaccinated with an authorized/approved COVID-19 vaccine induces an immune response that is non-inferior to the response induced by a two-dose priming series with the monovalent vaccine, and superior to that observed immediately before booster. - To demonstrate that two doses of monovalent (B.1.351)-AS03 or bivalent (D614 + B.1.351)-AS03 SARS-CoV-2 vaccine induce an immune response that is non inferior to the response induced by monovalent (D614)-AS03 vaccine. The secondary objectives of the study are: - To assess the neutralizing and binding antibody profiles after primary series vaccination at pre-defined time points during the study. - To assess the neutralizing and binding antibody responses of booster vaccination. - To describe the occurrences of laboratory-confirmed symptomatic COVID-19 after primary series and booster vaccination. - To describe the occurrences of serologically-confirmed SARS-CoV-2 infection after primary series vaccination.

NCT ID: NCT04721197 Active, not recruiting - Malnutrition, Child Clinical Trials

Hens Hatching Hope

Start date: January 23, 2021
Phase: N/A
Study type: Interventional

The study is a prospective community-cluster non-randomized trial that will evaluate the effectiveness of a program that will provide 30-day egg vouchers to mothers of 6 to 24 month-old children living in rural areas of Intibucá, Honduras.

NCT ID: NCT04394455 Enrolling by invitation - Anxiety Clinical Trials

Brief Cognitive Behavioral Therapy Versus Crisis Intervention Therapy Through Telepsychiatry on Psychiatric Symptoms

Start date: June 30, 2020
Phase: N/A
Study type: Interventional

The purpose of this randomized controlled trial is to determine the effect of two behavioral interventions: brief cognitive-behavioral therapy and crisis intervention therapy through telepsychiatry, over the level of perceived stress, anxiety, depression and post-traumatic stress symptoms during the COVID-19 pandemic in medical residents and medical staff at three hospitals in two cities of Honduras.

NCT ID: NCT04114006 Recruiting - Gastric Cancer Clinical Trials

Novel Screening Modality for Early Gastric Cancer

Start date: January 1, 2020
Phase:
Study type: Observational

Potential patients will be recruited at participating sites based on routine care with clinical indications for upper endoscopy. After careful review of their inclusion and exclusion criteria, patients will be approached regarding the study and if interested, they will be consented and usual standard of care procedures performed. Patients will undergo their scheduled endoscopy with standard forceps biopsies along with WATS brush samples. Documentation of the consent process and procedure will be done as well as data collection related to this study. All samples including standard of care samples and WATS samples will be sent for histologic analysis.

NCT ID: NCT04041453 Completed - Helminthiasis Clinical Trials

Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients

HI4T
Start date: October 9, 2019
Phase: Phase 2
Study type: Interventional

There are four species of intestinal worms collectively known as soil-transmitted helminthiasis (STH): Ancylostoma duodenale and Necator americanus (hookworms), Ascaris lumbricoides (roundworms), and Trichuris trichiura (whipworms). These parasites affect over two billion people and contribute to significant morbidity and disability, especially in high risk groups, for example children, agricultural workers and pregnant women. In children, STH are associated with impaired nutritional status evidenced by stunting, thinness and underweight. As is the case in most Latin America, STH are a public health problem in Honduras. The World Health Organization (WHO) informs that more than 2.5 million children (under 15 years of age) in the country are at risk of infection. To control these infections Honduras has established a national deworming program that operates since 2001 but despite these efforts, the prevalence of STH infections remains unacceptably high. This is especially true in rural communities where prevalence can be as high as 70% of the children population. Ivermectin (IVM) in combination with albendazole (ALB) has demonstrated the capacity to improve efficacy compared to any of these drugs in monotherapy; the efficacy is however, still inadequate in terms of cure rate, although egg reduction rates are significant. The purpose of the current trial is to assess the safety and efficacy of 3 experimental regimens for the treatment of infections by Trichuris trichiura in children in comparison with the current standard of practice in Mass Drug Administration (MDA) campaigns. The experimental regimens will explore the effect of multiple day regimens and high dose ivermectin. Treatment arms: - Group 1: single dose of ALB 400 mg. (active control arm). N:39 - Group 2: single dose ALB 400mg + IVM 600µg/Kg. N: 57 - Group 3: daily dose ALB 400mg for 3 consecutive days. N:24 - Group 4: daily dose ALB 400mg + IVM 600µg for 3 consecutive days. N:57 Total Study Population: 177

NCT ID: NCT03976830 Recruiting - Clinical trials for Nutrition in Cancer Survival and Treatment

Nutrition in Pediatric Oncology in Central America

Start date: January 1, 2019
Phase:
Study type: Observational

This study investigates nutritional status, at predefined points in therapy, and the association with outcomes in children and adolescents undergoing treatment for cancer in institutions under Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA) consortium in Central America. The aim of the study is to examine the effects of the newly-established nutritional program aimed at improving the delivery of nutritional care and outcomes in children undergoing treatment for cancer in Central America.

NCT ID: NCT03932682 Active, not recruiting - Influenza, Human Clinical Trials

Efficacy Study With QIVc in Pediatric Subjects

Start date: May 13, 2019
Phase: Phase 3
Study type: Interventional

This phase 3 clinical study is a randomized, observer-blind, multicenter study of QIVc versus a non-influenza vaccine in subjects 6 months though 47 months of age. The purpose of this study is to evaluate efficacy of QIVc in the prevention of Reverse transcription polymerase chain reaction (RT-PCR) confirmed influenza A or B disease in children 6 through 47 months of age, compared to a non-influenza vaccine.